A recent article on the approval of Forest/Mylan's Bystolic (nebivolol) incorrectly reported that it was the combination trial of Bystolic submitted in the NDA that established a different efficacy profile in black subjects; it was actually a trial published in the November 2007 issue of the Journal of Clinical Hypertension that found Bystolic to significantly reduce sitting diastolic and systolic blood pressure as monotherapy among blacks with stage I-II hypertension (1"The Pink Sheet" Jan. 7, 2008, p. 5)...
You may also be interested in...
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class
Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.
Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.